Abstract
Objective With the emergence of coronavirus disease 2019 (COVID-19) countries had to establish COVID-19 surveillance by adapting existing systems, such as the mandatory notification system and syndromic surveillance systems. We estimated COVID-19 hospitalization and ICU burden from existing severe acute respiratory infections (SARI) surveillance and compared it to COVID-19 notification data.
Methods Using data from the ICD-10 based hospital sentinel, we estimated SARI incidence and validated our estimations retrospectively using full population data. We estimated age-specific incidences for COVID-19 hospitalization and ICU for the first three COVID-19 waves in Germany, based on information of SARI cases (COVID-SARI). We compared these estimations to hospitalization and ICU burden of COVID-19 from notification data and described potential underreporting of hospitalizations in notification data.
Findings The estimation of SARI incidence from sentinel data corresponded very well to full population data. The estimated COVID-SARI incidence matched the notified COVID-19 hospitalization incidence in the first wave, but was much higher during the second and the third wave. The proportion of unknown hospitalization status among notified COVID-19 cases was much higher in the later waves compared to the first wave. For all waves, the ICU incidence estimated from COVID-SARI was considerably higher than the results from notification data.
Conclusion The use of SARI sentinel data adds valid and important information for assessing COVID-19 hospitalization and ICU burden, especially in times with high case numbers where notification data may be more incomplete.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of Kristin Tolksdorf was funded as a research project by the German ministry of health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Aerztekammer Berlin KdoeR waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
